Clinical Trials Sponsored by Tiziana Marangon

Total 245 results

Tiziana Marangon

Terminated

Study of Vorinostat Plus Melphalan and Prednisone (Zmp) in Advanced, Refractory Multiple Myeloma Patients

Multiple Myeloma

Italy
Tiziana Marangon

Withdrawn

Vorinostat Plus Lenalidomide and Dexamethasone or Lenalidomide Plus Dexamethasone in Multiple Myeloma Patients Who Experience Biochemical Relapse During Lenalidomide Maintenance Therapy (ZLd_Ld)

Multiple Myeloma

Italy
Tiziana Life Sciences LTD

Withdrawn

A Study of Oral Foralumab in Participants With Moderate to Severely Active Crohn's Disease

Crohn's Disease
Tiziana Life Sciences LTD

Withdrawn

Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS

Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis
Tiziana Life Sciences LTD

Completed

Study of Milciclib in Patients With Unresectable/Metastatic Hepatocellular Carcinoma

Hepatocellular Carcinoma

Israel, Greece, Italy
Tiziana Life Sciences LTD

Not yet recruiting

Milciclib in Combination With Gemcitabine in Advanced NSCLC

NSCLC
Tiziana Life Sciences LTD

Terminated

Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy

Malignant Thymoma

United States, Italy
Tiziana Life Sciences LTD

Terminated

Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma

Thymic Carcinoma

United States, France, Italy
Tiziana Life Sciences LTD

Recruiting

A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients

Secondary Progressive Multiple Sclerosis

United States
Tiziana Life Sciences LTD

Withdrawn

In-patient COVID-19 Study of Intranasal Foralumab

Covid19 | COVID-19 Respiratory Infection | COVID-19 Lower Respiratory Infection
Tiziana Life Sciences LTD

Withdrawn

Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM

NAFLD | NASH - Nonalcoholic Steatohepatitis | T2DM (Type 2 Diabetes Mellitus)
Celso Arango
Comunidad de Madrid

Completed

Intervention Module AGES (AGES-CM)

Psychosis

Spain
Tizona Therapeutics, Inc

Active, not recruiting

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Cancer

United States
Hospital General Universitario Gregorio Marañon
Fundación para la Investigación Biomédica del Hospital Gregorio Maranon

Completed

The Microbiome as a Target for Precision Medicine in Atherosclerosis (MIGATER)

Atherosclerosis | Acute Coronary Syndrome

Spain
Mariel Viviana Gómez
Maimonides University

Completed

Healing After Connective Tissue Graft Harvesting in the Palatal Area With and Without Suture

Wound Healing

Argentina
PharmaCotherapia d.o.o.
Hospital Ángeles Tijuana

Unknown

PCO-02 - Safety and Pharmacokinetics Trial

Healthy Volunteers

Mexico
Paragon 28

Completed

Multi-Plane Hallux Valgus Correction With the Phantom® Nail

Bunion | Hallux Valgus | Arthrodesis

United States
Paragon 28

Completed

Monster Screw System Post-Market Clinical Follow-Up Study

Ankle Injuries | Foot Injury

United States
Paragon 28

Completed

Grappler Interference Screw Post-Market Collection of Patient Reported Outcome Measures

Ankle Injuries | Achilles Tendon Rupture | Ankle Sprains | Syndesmotic Injuries | Ankle Inversion Sprain | Flexor Digitorum Longus on the Right | Flexor Digitorum Longus on the Left | Deltoid Ankle Sprain | Flexor Hallucis Longus on the Left | Flexor Hallucis Longus on the Right

United States
Paragon 28

Recruiting

Patient Specific Talus Spacer Post Approval Study

Avascular Necrosis of the Talus

United States
Paragon 28

Withdrawn

Evaluation of the Titan 3-D™ Wedge System

Flat Foot | Lateral Column Lengthening | Medial Cuneiform Osteotomy
Paragon 28

Completed

Grappler® Interference Screw Post-Market Clinical Follow-Up Study

Ankle Injuries | Achilles Tendon Rupture | Ankle Sprains | Syndesmotic Injuries | Ankle Inversion Sprain | Flexor Digitorum Longus on the Right | Flexor Digitorum Longus on the Left | Deltoid Ankle Sprain | Flexor Hallucis Longus on the Left | Flexor Hallucis Longus on the Right

United States
Paragon 28

Terminated

Early Weight-Bearing After Lapidus Arthrodesis

Bunion | Hallux Valgus | Arthrodesis

United States
Tatiana Besse-Hammer

Completed

Clinical and Dynamic Floor MRI Evaluation Before and After Prolapse Surgery

Prolapse

Belgium
Marathon Pharmaceuticals, LLC

Withdrawn

A Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Investigational Product MP-101 in Subjects With Short Bowel Syndrome Who Have Had an Inadequate Response to Anti-Diarrheals

Short Bowel Syndrome | Short Gut Syndrome | SBS | Short Gut | Short Bowel

United States
Marathon Pharmaceuticals, LLC

Withdrawn

A Open Label Extension Study for Subjects That Complete Study MP-101-CL-001

Short Bowel Syndrome | Short Gut Syndrome | SBS | Short Gut

United States
Tatiana Besse-Hammer

Completed

The Caregiver's Burden in Cerebral Palsy

Cerebral Palsy

Belgium
Tatiana Besse-Hammer

Completed

Heart Rate Variability as a Clinical Marker in a Population of Anxio-depressive Patients

Anxio Depressive Disorder

Belgium
Tatiana Besse-Hammer

Completed

Study of the Synergistic Effects of Biofeedback and Transcranial Electrical Stimulation in Anxio-depressive Disorders

Anxiety Depression

Belgium
Paragon Vision Sciences

Completed

High Refractive Index Material 510(k) (PVS-07-07)

Myopia | Hyperopia

United States
Marengo Therapeutics, Inc.

Recruiting

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors (START-001)

Neoplasms | Urogenital Neoplasms | Neoplasms by Site | Carcinoma | Epstein-Barr Virus Infections | Advanced Solid Tumors | Vulvar Neoplasms | Vulvar Diseases | Abdominal Neoplasm | Lung Neoplasm | Papillomavirus Infection | Genital Neoplasm, Female

United States, Canada
Paragon Vision Sciences

Completed

Corneal Refractive Therapy Design Comparison for -4 to -6 Diopter Treatment for Overnight Wear for Myopia

Myopia

United States
Marathon Family Health Team

Not yet recruiting

A Rural OPTIFAST Intervention for Partial Remission of Type 2 Diabetes in Adults With Obesity

Obesity | Diabetes Mellitus, Type 2
Hospital General Universitario Gregorio Marañon
Instituto de Salud Carlos III; Fundación para la Investigación Biomédica del...

Completed

Heparin Versus Saline in Peripheral Venous Catheter

Catheter-Related Infections

Spain
Aragon Pharmaceuticals, Inc.

Recruiting

A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer

Prostatic Neoplasms, Castration-Resistant

Moldova, Republic of, Spain
Aragon Pharmaceuticals, Inc.

Active, not recruiting

Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)

Prostate Cancer

United States
Aragon Pharmaceuticals, Inc.

Active, not recruiting

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

Prostatic Neoplasms

United States, France, Poland, Taiwan, Ukraine, United Kingdom, China, Belgium, Germany, Spain, Israel, Mexico, Malaysia, Romania, Turkey, Canada, Netherlands, Korea, Republic of, Brazil, Russian Federation, Argentina, Sweden, Czechia
Aragon Pharmaceuticals, Inc.

Active, not recruiting

A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms | Metastatic Castration-Resistant Prostate Cancer

United States, Canada, Netherlands, United Kingdom
Aragon Pharmaceuticals, Inc.

Completed

Study to Assess Drug-Drug Interaction Between Itraconazole or Gemfibrozil and JNJ-56021927

Healthy

United States
Aragon Pharmaceuticals, Inc.

Active, not recruiting

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

Prostatic Neoplasms

United States, Australia, France, Germany, United Kingdom, Belgium, Spain, Argentina, South Africa, Japan, Canada, Netherlands, Korea, Republic of, Brazil, Russian Federation, Mexico
Aragon Pharmaceuticals, Inc.

Active, not recruiting

A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer (SPARTAN)

Prostatic Neoplasms

United States, Australia, France, Poland, United Kingdom, Germany, Taiwan, Spain, Belgium, Israel, Romania, Japan, Canada, Denmark, Finland, Korea, Republic of, Netherlands, New Zealand, Russian Federation, Hungary, Austria, Sweden, Slovaki... and more
Aragon Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With Mild or Moderate Hepatic Impairment Compared With Participants With Normal Hepatic Function

Hepatic Impairment

United States
Aragon Pharmaceuticals, Inc.

Completed

14C-ARN-509 Microtracer Label AME and Absolute BA Study

Healthy

Netherlands
Aragon Pharmaceuticals, Inc.

Completed

Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate

Prostate Cancer

United States
Aragon Pharmaceuticals, Inc.

Active, not recruiting

A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC (TITAN)

Prostate Cancer

United States, France, Poland, Ukraine, United Kingdom, China, Spain, Argentina, Israel, Mexico, Romania, Turkey, Korea, Republic of, Japan, Sweden, Canada, Russian Federation, Brazil, Germany, Hungary, Czechia, Australia
Aragon Pharmaceuticals, Inc.

No longer available

An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms

Colombia, Brazil, Mexico
Aragon Pharmaceuticals, Inc.

Completed

A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study

Castration-Resistant Prostate Cancer

United States, Canada, Netherlands, United Kingdom, Moldova, Republic of
Aragon Pharmaceuticals, Inc.

Completed

The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer

Prostate Cancer

United States
Aragon Pharmaceuticals, Inc.

Completed

A Study to Assess the Relative Bioavailability of 7 Test Tablet Formulations of JNJ-56021927 With Respect to the Capsule Formulation of JNJ-56021927 in Healthy Male Participants

Healthy

United States
Aragon Pharmaceuticals, Inc.

Completed

Bioavailability Study of 3 Tablet Formulations vs. Capsule Formulation of JNJ-56021927 in Fasting Healthy Male Participants

Healthy

United States

Clinical Trials Sponsored by Tiziana Marangon

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sweden

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations